This interview is with Seth Berge, Founder, CEO, Regenerative Revival.
As Founder and CEO of Regenerative Revival and Precision Biologics, how would you describe your work in bringing regenerative therapies, peptides, and hormone optimization to patients and clinics nationwide?
Honestly, the simplest way I describe it is that we’re trying to give people back the version of themselves that got buried under fatigue, joint pain, and hormones that quietly went sideways over a decade.
Regenerative Revival and Precision Biologics exist because I kept seeing the same pattern — someone goes to their doctor, gets fifteen minutes and a referral to three other specialists, and leaves with a partial answer to a problem that touches their whole body. Nobody’s actually looking at the whole picture.
So what we’ve built is a physician-led model where stem cells, peptides, exosomes, and hormone optimization aren’t separate services stacked on top of each other — they’re a single coordinated protocol built around a person’s actual labs and their actual life. We now deliver much of this in-home, with a licensed nurse practitioner traveling to the patient instead of the patient having to track down a specialty clinic, because access shouldn’t depend on which ZIP code you live in.
I didn’t come into healthcare from a traditional medical background — I came in because I was obsessed with the gap between what patients wanted answered and what the system was actually built to answer. That’s still the whole job, honestly: close that gap, and do it in a way that’s rigorous enough that a physician would stake their name on it.
What career experiences—from building sales organizations to leading concierge and telehealth healthcare companies—most prepared you to build a business in regenerative medicine?
If Im being honest, none of it looks like a straight line until you zoom out. I spent years building sales organizations across financial services, home improvement, and solarcompletely different industries on the surface, but the same skill kept transferring: you learn to read what someone actually needs versus what they say they need, and you learn to build a team that can deliver that consistently, rather than relying on you to do it once.
The concierge and telehealth work is where it clicked for regenerative medicine specifically. Running a telehealth model teaches you quickly that access is the whole battleit doesnt matter how good your protocol is if a patient in a smaller market cant get to it. Thats directly why Regenerative Revival is structured the way it is now, with in-home delivery instead of forcing people to find a clinic three states away.
Running concierge healthcare taught me the other halfthat patients in this kind of care dont want to be handed off between five different specialists who never talk to each other. They want one team that actually looks at the whole picture. By the time I got to regenerative medicine, I wasnt learning that lesson for the first time. I already knew coordinated care and real access were non-negotiable; I just finally had a therapystem cells, peptides, hormone optimizationwhere getting that right actually changes someones quality of life, not just their convenience.
When you introduced enhanced protocols such as including exosomes with stem-cell treatments, what did that experience teach you about designing a patient experience that earns trust and referrals?
Adding exosomes alongside stem cell treatment taught me something I probably should have known going in: trust is not built by promising more; it is built by being straight about what is actually proven and what is still emerging. Exosomes are exciting—the early data on how they carry repair signals to tissue is genuinely interesting—but the honest answer is that the clinical evidence behind them is not as mature yet as what we have for mesenchymal stem cells. So when we started offering them, I made a rule: no one on our team pitches exosomes as a guaranteed upgrade. We tell patients exactly where the science stands—what is well-documented and what is still early-stage—and let them make the call with real information instead of a sales pitch dressed up as medicine.
What I did not expect was that being so direct is actually what drives referrals. Patients talk to each other, and what they tell their friends is not “the clinic promised me a miracle”—it is “they told me exactly what to expect, and it happened.” That is the whole trust equation in this field. People are already skeptical of regenerative medicine because they have seen providers overpromise, so the fastest way to lose someone forever is to be the clinic that does the same. The fastest way to earn a referral is to be the one that did not need to.
If there is a lesson from rolling out exosomes specifically, it is this: the protocol earns trust, but the conversation around the protocol is what earns the referral. We treat every new modality we add the same way now—lead with what the evidence actually supports, not with what would sound better in a headline.
For founders entering a healthcare category that patients may not fully understand, what is one practical way to educate prospective clients without relying on hype or overselling outcomes?
The one thing that has actually worked for us is treating education as the marketing, rather than treating marketing as something separate from education. Early on, we made a deliberate choice to put our budget into content that actually teaches people what precision biologics are, how they work, who is really a good candidate, and what the regulatory picture looks like — the kind of things patients are already searching for at 11 p.m. because their doctor gave them five minutes and three referrals. If you answer those questions honestly, including parts that aren’t flattering — for example, being upfront that exosome research is earlier-stage than stem cell research, or that this isn’t a miracle cure but a coordinated protocol — people actually trust you more, not less.
The practical version of this is: don’t run ads promising outcomes; publish real answers to the real questions your patients are already typing into Google. We built entire pieces around exactly that — the most common questions people ask about precision biologics: straight answers, no fluff, and citations of actual FDA guidance and clinical literature instead of vague claims. That content does more to convert a skeptical patient than any ad ever could, because it respects that they are smart enough to want the real picture before they commit to anything.
The trap founders fall into in a category patients don’t yet understand is thinking that hype creates urgency. It doesn’t — it creates suspicion, especially in healthcare, where people have been burned by overpromising. Clarity creates urgency. If someone finally understands what’s actually happening to their body and what their real options are, they don’t need to be sold; they just need someone to have been straight with them first.
How do you and your team decide when a person may be an appropriate candidate for a regenerative, peptide, or hormone-focused program—and when a conventional specialist referral or another option is more appropriate?
This is probably the question I care most about getting right, because the easy, lazy version of this business is to say yes to everyone who can pay. We don’t do that. Honestly, saying no to the wrong candidate is just as important as saying yes to the right one.
The way it actually works is that every person goes through a real evaluation before we ever discuss a protocol — labs, imaging where relevant, and a real conversation about their history, not a checklist. We’re looking for things such as localized tissue damage, chronic inflammation that hasn’t responded to standard care, someone who has tried the conventional route and plateaued, or someone dealing with hormone decline that is measurable, not just a feeling. Tissue health matters more to us than chronological age — I’ve seen a 55-year-old who is dialed in on their metabolic health respond better than a 40-year-old who is not. So we’re not just looking at a birthdate; we’re looking at the whole picture.
On the flip side, there are clear reasons we say, “this isn’t the right fit right now, or maybe ever.” Active infection, certain autoimmune flares, severe immunosuppression, advanced malignancy — those all require physician evaluation before we’d even consider a protocol, and sometimes the honest answer is that a patient needs a conventional specialist first, or instead. If someone is at end-stage joint failure, I’m not going to pretend a biologic is going to do what surgery needs to do. That’s not a business decision; it’s about not lying to someone about their own body.
The way I think about it is that our job isn’t to be the answer for everyone who walks through the door. It’s to be the right answer for the people we can actually help and to be honest enough to point everyone else somewhere better. That’s what makes the individual assessment step non-negotiable for us — not a formality, not a sales funnel, but an actual clinical decision made by someone qualified to make it.
As your telehealth offerings expand into hormone optimization and peptides, what operating practice has been most important for maintaining consistent clinical oversight across a nationwide patient base?
The thing that has mattered most, honestly, is refusing to let the model get looser just because we’re scaling. It would be easy, as you expand into more states, to let hormone optimization and peptide protocols drift toward something standardized — same dose, same script, minimal oversight — because that’s simpler to operate at scale. We’ve done the opposite on purpose.
Every patient sits inside one unified medical record, no matter what state they’re in or which piece of the protocol they’re on that month. Their hormone panel informs their peptide plan, which informs how we’re thinking about their joint or recovery protocol if they’re doing regenerative work too — it’s not five separate silos that happen to share a billing system. And every adjustment, every renewal, ties back to actual labs and a physician actually reviewing them. This is not a subscription that auto-renews because thirty days have passed.
The other non-negotiable is that a nurse practitioner operating alone is not our model. There’s a physician-led team behind every protocol, and that oversight doesn’t get thinner as we add states — if anything, we’ve had to build more infrastructure, not less, to make sure that’s true everywhere we operate, not just in our home market.
If I had to boil it down to one practice: we scaled the record-keeping and the physician review before we scaled the patient volume, not after. A lot of telehealth companies learn that lesson the hard way, after something has already gone wrong. We built it in from the start because, in this category, consistency isn’t a nice-to-have — it’s the entire thing that separates a legitimate clinical protocol from a subscription box that happens to involve needles.
What have you learned from serving both professional athletes and everyday patients about setting realistic goals for recovery, performance, or healthy aging?
What’s interesting is that professional athletes and everyday patients come in asking almost the same question in different words. The athlete wants to know how fast they can get back on the field. The 52-year-old with a bad knee wants to know if they can play with their grandkids without pain by the fall. Different stakes, same underlying need: tell me what’s actually realistic, not what they want to hear.
The athletes taught me to be precise about timelines, because their whole career runs on precision. They don’t want vague reassurance; they want the real biology — that this isn’t a one-session fix, that tissue remodeling happens over weeks to months, not overnight, and that rushing back before that process finishes just sets them up to re-injure. Once I got comfortable being that specific with elite athletes, it made me realize everyday patients deserve the exact same level of honesty, not a softer, vaguer version of it because we assume they won’t understand the details.
What everyday patients taught me is something the athletes already knew instinctively: recovery isn’t just the protocol, it’s everything around it. Nutrition, movement, sleep, hormone balance — all of it is the environment the biologic or the peptide is working inside. An athlete has a team managing all of that already. A regular patient usually doesn’t, so part of our job became coaching people through that whole picture, not just administering a treatment and sending them home.
If there’s one thing both groups taught me, it’s that setting a realistic goal isn’t a downgrade from an exciting one; it’s what actually gets people to trust the process long enough to see it through. The patients and athletes who do best are the ones who understood upfront that this is a few months of steady progress, not a single appointment that changes everything. That’s not the sexy sales pitch. It’s just what’s true, and I’ve learned it’s also what people actually respond to.
For clinic owners sourcing biologics or peptide-related products, what due-diligence step do you believe is essential before adding a new therapy to their patient offerings?
If I had to boil it down to one step that actually matters, it is this: don’t take a supplier’s word for anything — get them to show you the paperwork before you ever add a product to your offerings. Ask directly where the biologic actually comes from, how it is processed, and be specific about whether it is produced in an FDA-registered, cGMP-compliant facility. If a supplier is vague or defensive about that question, that is your answer right there: walk away.
The piece a lot of clinic owners skip is understanding the actual regulatory classification of what they are buying. Is this product operating under a section 361 exemption for minimally manipulated, homologous use, or does it actually require a full Biologics License Application under section 351? Those are two very different risk profiles, and I have seen clinic owners get into trouble because they assumed a supplier’s marketing language meant the same thing as regulatory compliance. It does not.
Beyond that, dig into the actual sourcing chain. For donor-derived products, you want to see that they’re following real protocols:
- healthy, consenting donors
- licensed medical collection
- serology testing
- independent lab sterility testing
- lot-based quarantine release aligned with AATB and AABB standards
- every legitimate lot should have its own identifier and a paper trail
If a representative can’t walk you through that without hesitation, that is diagnostic information about the entire company, not just that one product.
The honest reality is that this space has real variation in quality, and patients can’t see the difference between a rigorously sourced product and a shortcut — but their outcomes absolutely can. So the due diligence isn’t a box to check for legal cover; it is the thing that actually determines whether what you’re offering does what you’re telling patients it does. I’d rather turn down a cheaper supplier and sleep at night than find out six months in that I built patient trust on top of something I never actually verified.
Looking ahead, as longevity medicine moves into settings such as concierge care and luxury hospitality, what principle should business leaders follow to grow responsibly while keeping patient safety and informed consent at the center?
The principle I would hold onto, no matter how glamorous the setting becomes, is that a spa robe and a nice lobby do not change what a medical decision requires. As longevity medicine moves into concierge care and luxury hospitality — hotel wellness suites and retreat-style clinics — there is a real risk that the environment starts selling the experience while the actual clinical rigor quietly becomes an afterthought. That is backwards, and it is the first thing business leaders need to guard against as this space grows.
Informed consent is not a form you sign in a nice room; it is an actual conversation in which a patient understands what is proven, what is still emerging, and what the realistic timeline and outcome look like — before money changes hands, not buried in paperwork after they are already committed. If a business optimizes the experience to get someone to say yes faster instead of ensuring the person actually understands what they are agreeing to, that is the line I would tell any leader in this space not to cross.
The other piece is who is actually behind the protocol. Luxury settings are very good at creating an impression of exclusivity and expertise through atmosphere, but atmosphere is not physician oversight. I do not care how nice the setting is: if there is not a licensed clinician actually reviewing labs and making the clinical call, and instead staff are trained to upsell a menu of longevity services, that’s not medicine — it is retail wearing medicine’s clothes. Patients deserve to know the difference, and so do the people investing in these businesses.
So if I am giving one principle to hold onto as this category scales: let the setting serve the care, never the other way around. Growth in this space should mean more patients getting real, physician-led access to legitimate therapies, not a more polished version of the same shortcuts we are already seeing in less luxurious settings. The businesses that get this right would still pass every safety and consent standard even if you stripped away the hospitality and looked only at the medicine underneath. That is the bar. Everything else is decoration.
Thanks for sharing your knowledge and expertise. Is there anything else you'd like to add?
Just that I’d rather people remember one thing from this than ten — the whole reason I got into this space is that I kept watching patients get talked down to instead of talked with. Whether it’s a fifteen-minute appointment that addresses one problem and refers you elsewhere for the other four, or a supplement aisle promising you’ll feel twenty-five again, people in this industry have gotten used to being sold to instead of being leveled with. Everything we’ve built at Regenerative Revival and Precision Biologics is really just a bet that being straight with people — about what’s proven, what’s still early, what’s realistic, what isn’t — wins in the long run, even if it’s a slower way to grow a business.
I didn’t come up through medical school; I came up through sales floors, mastermind rooms, and a lot of trial and error, and I think that’s actually part of why I care so much about this. I know what it’s like to be on the other side of someone overpromising you something. So if there’s one thing I’d want a reader to take from this, it’s not a specific therapy or protocol — it’s that it’s worth asking hard questions of anyone in this space, us included, and walking away from anyone who doesn’t want to answer them.
I appreciate you having me — happy to keep the conversation going any time. People can find me on LinkedIn if they want to dig into any of this further.